Multiplexed 3D in vitro platform that combines multiple human tissues for preclinical drug testing.
| Date | Round | Amount |
|---|---|---|
| Jan 2026 | Seed Geneva-based FluoSphera raised a CHF 1.15 million seed led by Soulmates Ventures to scale its 3D human organ models that reduce clinical drug failures. | $1.4M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.